Pharma deals indicate promise of RNAi therapeutics

07/24/2008 | InPharm.com

Novartis has extended its collaboration with Alnylam Therapeutics and Roche has purchased gene-silencing specialist Mirus Bio Corp., an indication that the drug industry recognizes the research and commercial possibilities in RNAi-based therapeutics for a range of diseases. A Novartis official said RNAi "holds great potential," adding, "In particular, this new area of biology has potential to treat diseases that have not been able to be addressed by traditional approaches."

View Full Article in:

InPharm.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC